Niagen Bioscience(NAGE)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

NAGE Niagen Bioscience

交易中 06-29 09:36:22 EDT

3.38

-0.04

-1.17%

最高3.42	最低3.38	成交量2.31万
今开3.41	昨收3.42	日振幅1.32%
总市值2.70亿	流通市值1.74亿	总股本7,992万
成交额7.88万	换手率0.04%	流通股本5,141万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"NAGE","market":"US","secType":"STK","nameCN":"Niagen Bioscience","latestPrice":3.38,"timestamp":1782740181096,"preClose":3.42,"halted":0,"volume":23129,"delay":0,"changeRate":-0.01169590643274855,"floatShares":51414700,"shares":79919957,"eps":0.210015,"marketStatus":"交易中","change":-0.04,"latestTime":"06-29 09:36:22 EDT","open":3.41,"high":3.42,"low":3.375,"amount":78802.6447454,"amplitude":0.013158,"askPrice":3.39,"askSize":840,"bidPrice":3.38,"bidSize":141,"shortable":3,"etf":0,"ttmEps":0.210015,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1782763200000},"marketStatusCode":2,"adr":0,"exchange":"NASDAQ","adjPreClose":3.42,"preHourTrading":{"tag":"盘前","latestPrice":3.45,"preClose":3.42,"latestTime":"08:45 EDT","volume":447,"amount":1535.1499800000001,"timestamp":1782737103845,"change":0.03,"changeRate":0.008772,"amplitude":0.04152},"postHourTrading":{"tag":"盘后","latestPrice":3.4005,"preClose":3.42,"latestTime":"19:46 EDT","volume":136055,"amount":465202.275063,"timestamp":1782517600853,"change":-0.0195,"changeRate":-0.005702,"amplitude":0.017544},"volumeRatio":1.368102,"impliedVol":2.9392,"impliedVolPercentile":0.9442},"requestUrl":"/m/hq/s/NAGE","defaultTab":"news","newsList":[{"id":"2640941274","title":"Niagen Bioscience强化NAD+全球领导地位 外部研究项目更名","url":"https://stock-news.laohu8.com/highlight/detail?id=2640941274","media":"环球市场播报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640941274?lang=zh_cn&edition=full","pubTime":"2026-06-02 23:09","pubTimestamp":1780412940,"startTime":"0","endTime":"0","summary":"NAD+科学领域的全球权威企业Niagen Bioscience宣布，将其广受认可的“ChromaDex外部研究项目”正式更名为“Niagen研究项目”。此举紧随公司从ChromaDex更名为Niagen Bioscience的战略步伐，旨在通过其旗舰成分Niagen，集中力量推进对NAD+的理解与应用。　　此外，公司还启动了“Niagen Bioscience培训生资助计划”，每年将向专注于运动表现、恢复、疲劳及适应性等方向的研究生和博士后提供三项1万美元的资助，以培养下一代NAD+科研人才。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-06-02/doc-inhzzumh2976932.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4121","NAGE","BK4183","NAD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1115416670","title":"Niagen Bioscience将Olympia Pharmaceuticals纳入Niagen Plus™ 503B复合药物合作伙伴网络","url":"https://stock-news.laohu8.com/highlight/detail?id=1115416670","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1115416670?lang=zh_cn&edition=full","pubTime":"2026-04-28 20:37","pubTimestamp":1777379832,"startTime":"0","endTime":"0","summary":"Niagen Bioscience宣布与Olympia Pharmaceuticals达成合作，后者正式加入其503B复合药物合作伙伴网络，共同推进明星产品Niagen Plus™的市场布局。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4183","BK4121","NAGE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1115891551","title":"Niagen Bioscience携手USP制定首个NRCL专论，确立Niagen®专利成分标准","url":"https://stock-news.laohu8.com/highlight/detail?id=1115891551","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1115891551?lang=zh_cn&edition=full","pubTime":"2026-04-09 20:33","pubTimestamp":1775737993,"startTime":"0","endTime":"0","summary":"Niagen Bioscience与美国药典委员会（USP）达成合作，共同为氯化烟酰胺核糖（NRCL）——即Niagen®的专利形式——制定史上首个USP专论。这一里程碑式的合作旨在为NRCL建立权威的质量与纯度标准，为行业提供统一规范。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4121","NAGE","BK4183"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1100336940","title":"Niagen Bioscience与OneSpaWorld达成首项邮轮诊所合作，将NAD+增强型Niagen IV疗法引入远洋航行","url":"https://stock-news.laohu8.com/highlight/detail?id=1100336940","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1100336940?lang=zh_cn&edition=full","pubTime":"2026-03-31 20:35","pubTimestamp":1774960546,"startTime":"0","endTime":"0","summary":"Niagen Bioscience宣布与OneSpaWorld Holdings Limited达成首项邮轮诊所合作，将NAD+增强型Niagen IV疗法的健康益处带入远洋航行体验。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4183","BK4121","LU0128526141.USD","BK4192","OSW","LU0029874061.USD","NAGE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1171944922","title":"Niagen Bioscience与全球顶尖机构就Niagen®达成逾300项外部研究协议，助力45项临床研究发表","url":"https://stock-news.laohu8.com/highlight/detail?id=1171944922","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1171944922?lang=zh_cn&edition=full","pubTime":"2026-03-17 20:32","pubTimestamp":1773750774,"startTime":"0","endTime":"0","summary":"Niagen Bioscience近日宣布，其与全球多家顶尖科研机构就核心成分Niagen®签署的外部研究协议已突破300项。这一重要进展进一步推动了相关临床研究的发展，目前已有45项基于Niagen®的临床研究在权威期刊上正式发表。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NAGE","BK4121","BK4183"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1142110680","title":"Niagen Bioscience 2025财年净销售额同比增长30%至1.294亿美元，净利润激增103%至1740万美元，基本每股收益0.22美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1142110680","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1142110680?lang=zh_cn&edition=full","pubTime":"2026-03-05 05:03","pubTimestamp":1772658211,"startTime":"0","endTime":"0","summary":"Niagen Bioscience（股票代码：NAGE）近日公布了其2025财年财务业绩，表现亮眼。公司净销售额达到1.294亿美元，较去年同期大幅增长30%。盈利能力方面更是实现飞跃，净利润录得1740万美元，同比飙升103%。按基本每股收益计算，该公司2025财年实现每股收益0.22美元。\n这一强劲的增长势头主要得益于核心产品在市场中的需求持续旺盛以及公司运营效率的显著提升。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4183","NAGE","BK4121"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1104837583","title":"Niagen Bioscience通过全现金交易向LGC出售Chromadex参考标准业务，精简运营聚焦主业","url":"https://stock-news.laohu8.com/highlight/detail?id=1104837583","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1104837583?lang=zh_cn&edition=full","pubTime":"2026-02-26 20:10","pubTimestamp":1772107856,"startTime":"0","endTime":"0","summary":"Niagen Bioscience宣布将旗下Chromadex参考标准业务以全现金交易方式出售给LGC，旨在优化公司架构并集中资源发展核心业务。此次交易将帮助Niagen Bioscience进一步聚焦主营业务，提升运营效率。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4183","BK4121","NAGE"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.niagenplus.com","stockEarnings":[{"period":"1week","weight":-0.0229},{"period":"1month","weight":-0.107},{"period":"3month","weight":-0.1857},{"period":"6month","weight":-0.4849},{"period":"1year","weight":-0.7525},{"period":"ytd","weight":-0.4623}],"compareEarnings":[{"period":"1week","weight":-0.0238},{"period":"1month","weight":-0.0286},{"period":"3month","weight":0.1497},{"period":"6month","weight":0.056},{"period":"1year","weight":0.1914},{"period":"ytd","weight":0.069}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Niagen Bioscience, Inc.成立于2006年7月20日。Niagen是一家致力于健康老龄化的全球性生物科学公司。包括世界知名科学家在内的该公司团队正在开创性地研究烟酰胺腺嘌呤二核苷酸（NAD +），这是一种必需的辅酶，是细胞代谢的关键调节因子，存在于人体的每个细胞中。","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":-0.045249},{"month":2,"riseRate":0.5,"avgChangeRate":0.181088},{"month":3,"riseRate":0.3,"avgChangeRate":0.049759},{"month":4,"riseRate":0.6,"avgChangeRate":0.039691},{"month":5,"riseRate":0.454545,"avgChangeRate":0.002402},{"month":6,"riseRate":0.545455,"avgChangeRate":0.051685},{"month":7,"riseRate":0.5,"avgChangeRate":-0.007412},{"month":8,"riseRate":0.3,"avgChangeRate":-0.041379},{"month":9,"riseRate":0.3,"avgChangeRate":-0.054309},{"month":10,"riseRate":0.2,"avgChangeRate":-0.056092},{"month":11,"riseRate":0.7,"avgChangeRate":0.200397},{"month":12,"riseRate":0.3,"avgChangeRate":-0.024057}],"exchange":"NASDAQ","name":"Niagen Bioscience","nameEN":"Niagen Bioscience"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Niagen Bioscience(NAGE)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Niagen Bioscience(NAGE)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Niagen Bioscience,NAGE,Niagen Bioscience股票,Niagen Bioscience股票老虎,Niagen Bioscience股票老虎国际,Niagen Bioscience行情,Niagen Bioscience股票行情,Niagen Bioscience股价,Niagen Bioscience股市,Niagen Bioscience股票价格,Niagen Bioscience股票交易,Niagen Bioscience股票购买,Niagen Bioscience股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Niagen Bioscience(NAGE)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Niagen Bioscience(NAGE)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}